@article{MTMT:31591917,
	title = {Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure},
	url = {https://m2.mtmt.hu/api/publication/31591917},
	author = {Packer, Milton and Anker, Stefan D. and Butler, Javed and Filippatos, Gerasimos and Pocock, Stuart J. and Carson, Peter and Januzzi, James and Verma, Subodh and Tsutsui, Hiroyuki and Brueckmann, Martina and Jamal, Waheed and Kimura, Karen and Schnee, Janet and Zeller, Cordula and Cotton, Daniel and Bocchi, Edimar and Böhm, Michael and Choi, Dong-Ju and Chopra, Vijay and Chuquiure, Eduardo and Giannetti, Nadia and Janssens, Stefan and Zhang, Jian and Gonzalez Juanatey, Jose R. and Kaul, Sanjay and Brunner-La Rocca, Hans-Peter and Merkely, Béla Péter and Nicholls, Stephen J. and Perrone, Sergio and Pina, Ileana and Ponikowski, Piotr and Sattar, Naveed and Senni, Michele and Seronde, Marie-France and Spinar, Jindrich and Squire, Iain and Taddei, Stefano and Wanner, Christoph and Zannad, Faiez},
	doi = {10.1056/NEJMoa2022190},
	journal-iso = {NEW ENGL J MED},
	journal = {NEW ENGLAND JOURNAL OF MEDICINE},
	volume = {383},
	unique-id = {31591917},
	issn = {0028-4793},
	year = {2020},
	eissn = {1533-4406},
	pages = {1413-1424},
	orcid-numbers = {Merkely, Béla Péter/0000-0001-6514-0723}
}

@article{MTMT:30828891,
	title = {Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.},
	url = {https://m2.mtmt.hu/api/publication/30828891},
	author = {McMurray, John J V and Solomon, Scott D and Inzucchi, Silvio E and Køber, Lars and Kosiborod, Mikhail N and Martinez, Felipe A and Ponikowski, Piotr and Sabatine, Marc S and Anand, Inder S and Bělohlávek, Jan and Böhm, Michael and Chiang, Chern-En and Chopra, Vijay K and de Boer, Rudolf A and Desai, Akshay S and Diez, Mirta and Drozdz, Jaroslaw and Dukát, Andrej and Ge, Junbo and Howlett, Jonathan G and Katova, Tzvetana and Kitakaze, Masafumi and Ljungman, Charlotta E A and Merkely, Béla Péter and Nicolau, Jose C and O'Meara, Eileen and Petrie, Mark C and Vinh, Pham N and Schou, Morten and Tereshchenko, Sergey and Verma, Subodh and Held, Claes and DeMets, David L and Docherty, Kieran F and Jhund, Pardeep S and Bengtsson, Olof and Sjöstrand, Mikaela and Langkilde, Anna-Maria},
	doi = {10.1056/NEJMoa1911303},
	journal-iso = {NEW ENGL J MED},
	journal = {NEW ENGLAND JOURNAL OF MEDICINE},
	volume = {381},
	unique-id = {30828891},
	issn = {0028-4793},
	abstract = {In patients with type 2 diabetes, inhibitors of sodium-glucose cotransporter 2 (SGLT2) reduce the risk of a first hospitalization for heart failure, possibly through glucose-independent mechanisms. More data are needed regarding the effects of SGLT2 inhibitors in patients with established heart failure and a reduced ejection fraction, regardless of the presence or absence of type 2 diabetes.In this phase 3, placebo-controlled trial, we randomly assigned 4744 patients with New York Heart Association class II, III, or IV heart failure and an ejection fraction of 40% or less to receive either dapagliflozin (at a dose of 10 mg once daily) or placebo, in addition to recommended therapy. The primary outcome was a composite of worsening heart failure (hospitalization or an urgent visit resulting in intravenous therapy for heart failure) or cardiovascular death.Over a median of 18.2 months, the primary outcome occurred in 386 of 2373 patients (16.3%) in the dapagliflozin group and in 502 of 2371 patients (21.2%) in the placebo group (hazard ratio, 0.74; 95% confidence interval [CI], 0.65 to 0.85; P<0.001). A first worsening heart failure event occurred in 237 patients (10.0%) in the dapagliflozin group and in 326 patients (13.7%) in the placebo group (hazard ratio, 0.70; 95% CI, 0.59 to 0.83). Death from cardiovascular causes occurred in 227 patients (9.6%) in the dapagliflozin group and in 273 patients (11.5%) in the placebo group (hazard ratio, 0.82; 95% CI, 0.69 to 0.98); 276 patients (11.6%) and 329 patients (13.9%), respectively, died from any cause (hazard ratio, 0.83; 95% CI, 0.71 to 0.97). Findings in patients with diabetes were similar to those in patients without diabetes. The frequency of adverse events related to volume depletion, renal dysfunction, and hypoglycemia did not differ between treatment groups.Among patients with heart failure and a reduced ejection fraction, the risk of worsening heart failure or death from cardiovascular causes was lower among those who received dapagliflozin than among those who received placebo, regardless of the presence or absence of diabetes. (Funded by AstraZeneca; DAPA-HF ClinicalTrials.gov number, NCT03036124.).},
	year = {2019},
	eissn = {1533-4406},
	pages = {1995-2008},
	orcid-numbers = {Merkely, Béla Péter/0000-0001-6514-0723}
}